Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22816953 | 0.95 | EPHX2 (0.59) | EPHX2TRPV1MAPTL3MBTL1KMT2A | |
| SCHEMBL12085977 | 0.88 | CYP17A1 (0.51) | EPHX2TRPV1HPGD | |
| SCHEMBL21515008 | 0.85 | CA12 (0.52) | EPHX2TRPV1MAPTKMT2AKDM4E | |
| SCHEMBL515175 | 0.85 | EPHX2 (0.71) | EPHX2TRPV1MAPTL3MBTL1KMT2A | |
| SCHEMBL13055402 | 0.84 | CYP17A1 (0.59) | L3MBTL1GAAALDH1A1 | |
| SCHEMBL7078666 | 0.83 | MAPT (0.51) | EPHX2MAPTL3MBTL1GAA | |
| SCHEMBL29131710 | 0.83 | HPGD (0.59) | MAPTL3MBTL1FAAHHPGDGAA | |
| SCHEMBL23389249 | 0.82 | CA1 (0.55) | EPHX2TRPV1L3MBTL1KMT2AKDM4E | |
| SCHEMBL1259785 | 0.82 | SCN10A (0.53) | MAPT | |
| SCHEMBL29991055 | 0.82 | NPC1 (0.55) | EPHX2MAPTHPGDGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319684-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-06-03 | — | — | US | disclosed |
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-11-25 | — | — | US | disclosed |
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-11-25 | — | — | US | disclosed |
| US-10988475-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988475-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200354355-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-11-12 | — | — | US | disclosed |
| US-20200354355-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-11-12 | — | — | US | disclosed |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-03 | — | — | US | disclosed |
| US-10570128-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-02-25 | — | — | US | disclosed |
| WO-2004098516-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-23 | — | — | US | disclosed |
| WO-2004071460-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | NOVARTIS AG (CH) | 2004-07-08 | — | — | US | disclosed |
| US-6713468-B2 | AS ANTICONVULSANTS; FOR THERAPY AND PROPHYLAXIS OF ISCHAEMIAS, ANOXIA, NEURODEGENERATIVE DISEASES | AVENTIS PHARMA S.A. (FR) | 2004-03-30 | — | — | US | disclosed |
| US-20030055031-A1 | Methods of using thiazolobenzoheterocycles | RHONE-POULENC RORER S.A. | 2003-03-20 | — | — | US | disclosed |
| US-6448241-B1 | THESE COMPOUNDS ARE ANTICONVULSANTS AND INTERFERE WITH GLUTAMATERGIC TRANSMISSION AND ARE THEREFORE USEFUL FOR THE TREATMENT OR PREVENTION OF ALL ISCHAEMIAS FOLLOWING CEREBROVASCULAR ACCIDENTS | AVENTIS PHARMA S.A. (FR) | 2002-09-10 | — | — | US | disclosed |
| US-6423715-B1 | ANTICONVULSANTS | AVENTIS PHARMA S.A. (FR) | 2002-07-23 | — | — | US | disclosed |
| US-6369221-B1 | Thiazolobenzoheterocycles, preparation and medicines containing same | AVENTIS PHARMA S.A. (FR) | 2002-04-09 | — | — | US | disclosed |
| US-6288075-B1 | ANTIEPILEPTIC AGENTS; NERVOUS SYSTEM, BRAIN, AND CARDIOVASCULAR DISORDERS | RHONE-POULENC RORER S.A. (FR) | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055031-A1 | Methods of using thiazolobenzoheterocycles | SLCO2B1, SLCO1B1, CYP21A2 | EPHX2 216/4885TRPV1 1574/4885MAPT 4138/4885 |
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | EPHX2 4231/4885TRPV1 571/4885MAPT 4140/4885 |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | EPHX2 1896/4885TRPV1 721/4885MAPT 4636/4885 |
| US-10570128-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | EPHX2 4231/4885TRPV1 571/4885MAPT 4140/4885 |
| US-12319684-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | EPHX2 4231/4885TRPV1 571/4885MAPT 4140/4885 |
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | CYP2A6, HCAR2, CYP2B6 | EPHX2 377/4885TRPV1 1286/4885MAPT 4281/4885 |
| US-10988475-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | EPHX2 4231/4885TRPV1 571/4885MAPT 4140/4885 |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | EIF4E, EIF4A1, EIF4A2 | EPHX2 4340/4885TRPV1 3970/4885MAPT 1569/4885 |
| US-20200354355-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | EPHX2 4231/4885TRPV1 571/4885MAPT 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.